Dr. Peter J. Goadsby is one of the world’s leading headache neurologists and researchers. He is Dean of Biomedical Sciences, King Abdullah University of Science and Technology, Saudi Arabia. Latterly, he has been a professor at King’s College London and is an emeritus professor at the University of California, Los Angeles (UCLA), and was previously Professor of Neurology, University of California, San Francisco. Dr. Goadsby is a Past President of the American Headache Society, the International Headache Society, and past Chair of the British Association for the Study of Headache. He is a trustee of The Migraine Trust and the Organisation for Understanding Cluster Headache, UK.
With his colleague Lars Edvinsson, they were the first to identify a role for calcitonin gene-related peptide (CGRP) in migraine, a discovery that has been instrumental in creating the new class of medications: CGRP blockers, including Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), Nurtec ODT (rimegepant), Qulipta (atogepant), and Vyepti (eptinezumab). In 2021, with others, they shared the Brain Prize for work in migraine.